Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Home
Publications
Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Authors:
ID
Inga Dammann
Inga Dammann
CR
Cathrin Rohleder
Cathrin Rohleder
FL
F. Markus Leweke
F. Markus Leweke
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Download PDF
Download
Publisher website
Google Scholar
7 May 2024
journal article
correction
Published by
Georg Thieme Verlag KG
in
Pharmacopsychiatry
Vol. 57
(03)
,
e2
DOI:
10.1055/a-2775-0902
Abstract
10.1055/a-2228-6118 In the above-mentioned article the COI has been updated. The correct COI is: FML is a shareholder of curantis UG (Ltd.) and received a research grant from Endosane Pharmaceuticals GmbH. Furthermore, FML is the co-founder and Medical Director of Endosane Pharmaceuticals GmbH, although this role operates through a consultancy agreement with curantis UG (Ltd.) as the primary affiliation. CR is a shareholder of lero bioscience UG (Ltd). CR and ID are currently employed by Endosane Pharmaceuticals GmbH. This was corrected in the online version on 09.02.2026. Article published online: 13 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Keywords
PSYCHIATRIC BENEFITS
CRITICAL REVIEW
ENDOSANE PHARMACEUTICALS
PHARMACEUTICALS GMBH
POTENTIAL EVIDENCE-BASED
EVIDENCE-BASED PSYCHIATRIC
PHARMACEUTICALS
CANNABIDIOL
BENEFITS
REVIEW
Related articles
Scroll to top